The eyedrops Larkin and his team developed contain a synthetic peptide that acts to block the pathways which cause the inflammation.
Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million, the company said Friday.
Bluebird Bio announced Friday it would sell itself and its portfolio of gene therapies to the investment firms Carlyle and SK ...
A 21-year-old harbor seal at Buttonwood Park Zoo in New Bedford, named Blue, died last week from highly pathogenic avian influenza, known as avian flu or bird flu. Diagnostic testing on Blue showed ...
Bluebird Bio announced it would sell itself and its portfolio of gene therapies to the investment firms Carlyle and SK ...
The Standard-Times on MSN48m
Buttonwood Park Zoo confirms popular seal Blue died from the avian fluButtonwood Park Zoo officials have confirmed that Blue, a 21-year-old harbor seal, died this month due to complications from the avian flu, or bird flu. Zoo officials say it's the second case of a ...
There is a catch. If the private equity firms can boost sales of bluebird’s three gene therapies to $600 million—over any ...
Stay up-to-date with the latest and best audio content from CBC Listen delivered to your inbox every two weeks.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback